Innocoll AG (INNL) was Initiated by FBR Capital to “Outperform” and the brokerage firm has set the Price Target at $18. FBR Capital advised their investors in a research report released on Jun 30, 2016.
Innocoll AG opened for trading at $5.09 and hit $5.1799 on the upside on Wednesday, eventually ending the session at $5.07, with a gain of 3.05% or 0.15 points. The heightened volatility saw the trading volume jump to 70,529 shares. Company has a market cap of $1,592 M.
Innocoll AG formerly Innocoll GmbH is a global commercial-stage specialty pharmaceutical company with late-stage development programs. The Company’s lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections or DFIs. The Company has initiated Phase III efficacy trials for Cogenzia in both the United States and Europe. The Company has initiated a pivotal pharmacokinetic study for XaraColl. CollaGUARD which prevents post-surgical adhesions is approved in 48 countries in Europe Asia the Middle East and Latin America. The Company products consist of CollatampG surgical implant RegenePro Durieva and Septocoll in a range of topical and implantable forms including sponges films membranes and gels compatible with a range of therapeutics including hydrophobic and hydrophilic active ingredients and small molecules and biologics. It also offers CollaCare Suite for wound care.